Faslodex (fulvestrant), a new drug for metastatic breast cancer

June 2002

You'll start hearing about Faslodex (fulvestrant), a new drug for metastatic breast cancer.

It's for postmenopausal women whose cancer progresses on tamoxifen or another antiestrogen.

In these women, Faslodex delays tumor progression at least as well as the aromatase inhibitor Arimidex (anastrozole).

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
200+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

Lots of news reports are causing patients to think that antidepressant drugs don't work any better than placebo
Infectious Diseases increasing resistance of strep throat to macrolides
Infectious Diseases no longer recommends using quinolones to treat gonorrhea in California or Hawaii
inhaled beta-agonists MIGHT increase the risk of heart attacks in COPD patients
Hematology & Oncology Faslodex (fulvestrant), a new drug for metastatic breast cancer
Hematology & Oncology the use of soy in women taking tamoxifen
Osteoporosis Actonel (risedronate) will soon come in a new 35 mg tablet for once-a-week dosing
Diabetes Media reports that "metformin is dangerous" have many diabetes patients worried
Women's Health two new alternatives to oral contraceptives...Ortho Evra and NuvaRing
Women's Health many women are asking how to discontinue HRT
Cardiology Benicar (olmesartan), a new angiotensin receptor blocker for hypertension
coenzyme Q10 to PREVENT migraines
New guidelines will help clarify how to treat bipolar disorder
Gastroenterology OTC laxatives that contain aloe or cascara will either go off the market or be reformulated
new home diagnostic test kits
Gastroenterology the approval of restricted use of Lotronex